Clinical Research Directory

Inclusion Criteria: * Male patients aged 40 years and older who were diagnosed with benign prostatic hyperplasia and underwent transurethral resection of the prostate (TURP) or a similar endoscopic prostate surgery were included in the study Exclusion Criteria: * Neurological Pathologies: * Diagnosis of neurogenic bladder. * History of Multiple Sclerosis, Parkinson's disease, or cerebrovascular accident (CVA). * Spinal cord injury or any other conditions leading to neurogenic bladder dysfunction. Metabolic and Systemic Diseases: * Diabetes Mellitus with associated neuropathy. * Severe renal impairment (eGFR \<30 ml/min/1.73 m²). * Severe hepatic impairment (Child-Pugh C). * Moderate hepatic impairment (Child-Pugh B) or severe renal impairment in patients using strong CYP3A inhibitors. Urinary System Related Pathologies: * Previous treatment with intravesical BoNT-A or Mirabegron. * Active urinary tract infection (confirmed by positive urine culture). * Presence of bladder tumor, bladder stones, or bladder diverticulum. * History of pelvic radiotherapy. * Urethral stricture or conditions carrying a risk of re-obstruction. Cardiovascular Risks (Contraindications for Mirabegron and Anticholinergics): * Uncontrolled hypertension (≥180/110 mmHg). * Severe cardiac arrhythmia or heart failure (NYHA Class III-IV). Other Exclusion Criteria: * Patients planning to receive other overactive bladder (OAB) treatments during the study period. * Incomplete follow-up data or missing medical records.